Med-Chemist : "Quintessential Medicinal Chemistry"
Showing posts with label
Treatment of Moderately-to-Severely Active Rheumatoid Arthritis
.
Show all posts
Showing posts with label
Treatment of Moderately-to-Severely Active Rheumatoid Arthritis
.
Show all posts
Thursday, August 23, 2018
FDA Advisory Committee Recommends the Approval of Baricitinib 2mg, but not 4mg, for the Treatment of Moderately-to-Severely Active Rheumatoid Arthritis
›
Eli Lilly and Company (NYSE: LLY) and Incyte Corporation (NASDAQ: INCY) announced that the U.S. Food and Drug Administration's (FDA) ...
›
Home
View web version
